BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Confirms Proceeds of C$1.5M from Warrant Exercise

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced its receipt of over C$1.5 million from the exercise of approximately 3.2 million common share purchase warrants at an average weighted exercise price of C$0.48 per share. The company intends to use the proceeds of the warrant exercise to advance its organic mustard plant-based crop protection technologies and for general working capital purposes. “Our shareholders have demonstrated strong support through continued exercise of warrants which further bolsters our cash position to over C$3.1 million,” said MustGrow CEO Corey Giasson. “A portion of the proceeds will be used to accelerate our disruptive pipeline assets, including our ground-breaking field studies in Colombia where we are working to provide a potential solution to combat the banana disease Fusarium wilt TR4.”

To view the full press release, visit https://ibn.fm/8Cyoq

About MustGrow Biologics Corp

MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. The company has approximately 37 million basic common shares issued and outstanding. For further details, please visit www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in NetworkNewsAudio Editorial on Voice-Based Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.  MindBio Therapeutics (CSE: MBIO; Frankfurt:…

1 hour ago

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet…

1 hour ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio audio press release focused on emerging opportunities in central nervous…

1 hour ago

BioMedNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.…

3 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports First-Quarter Results, Highlights Progress Across Biotech Platform

Oncotelic Therapeutics (OTCQB: OTLC) reported first-quarter 2026 financial results and a corporate update highlighting continued…

3 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies…

1 day ago